Introduction: The aim of the study was to survey current practices for preventing recurrent stone disease in an outpatient clinic setting in Germany. Methods: Two invitations to complete an anonymous REDCap® survey were emailed to members of the occupational union of German urologists who work as outpatient urologists (“Berufsverband Deutscher Urologen e.V.”). The survey included questions on diagnostic modalities and counselling to prevent stone disease. Results: A total of 130 outpatient urologists completed the survey. 84.6% of urologists give general advice to first-time stone formers. Recommendations comprise increased fluid uptake in 100%, two-thirds advice on calcium and oxalate intake, and one-third on salt and protein intake. 64.6% perform a metabolic evaluation for high-risk stone formers. However, patients with risk factors other than repeat stone disease are often overlooked. Urologists agreed that a lack of time (73.1%) and reimbursement (64.6%), as well as insufficient patient compliance (60.8%), pose significant challenges. The majority of urologists agreed that training is required. Conclusion: General recommendations for stone formers are usually provided, but nutritional advice tends to be incomplete. Our results raise quality-of-care concerns: Metabolic evaluation of stone formers at high risk of recurrence is uncommon. Structural changes are required due to time constraints, and poor remuneration must be addressed to improve patient care.

1.
Trinchieri
A
,
Dormia
G
,
Montanari
E
,
Zanetti
G
.
Cystinuria: definition, epidemiology and clinical aspects
.
Arch Ital Urol Androl
.
2004
;
76
:
129
34
.
2.
Tiselius
HG
.
Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?
Urolithiasis
.
2016
;
44
:
91
100
. .
3.
Scales
CD
,
Smith
AC
,
Hanley
JM
,
Saigal
CS
.
Prevalence of kidney stones in the United States
.
Eur Urol
.
2012
;
62
:
160
5
. .
4.
Daudon
M
,
Jungers
P
,
Bazin
D
,
Williams
JC
.
Recurrence rates of urinary calculi according to stone composition and morphology
.
Urolithiasis
.
2018
;
46
:
459
70
. .
5.
Pearle
MS
,
Goldfarb
DS
,
Assimos
DG
,
Curhan
G
,
Denu-Ciocca
CJ
,
Matlaga
BR
,
Medical management of kidney stones: AUA guideline
.
J Urol
.
2014
;
192
:
316
24
.
6.
Türk
C
,
Neisius
A
,
Petřík
A
.
Guidelines on urolithiasis
.
European Association of Urology
;
2021
. Available from: http://uroweb.org/guideline/urolithiasis/.
7.
Tiselius
HG
,
Daudon
M
,
Thomas
K
,
Seitz
C
.
Metabolic work-up of patients with urolithiasis: indications and diagnostic algorithm
.
Eur Urol Focus
.
2017
;
3
:
62
71
. .
8.
Wertheim
ML
,
Nakada
SY
,
Penniston
KL
.
Current practice patterns of urologists providing nutrition recommendations to patients with kidney stones
.
J Endourol
.
2014
;
28
:
1127
31
. .
9.
Reicherz
A
,
Rausch
P
,
Herout
R
,
Noldus
J
,
Bach
P
.
An empirical study on hospital-based prevention of recurrent urinary stone disease in Germany
.
World J Urol
.
2022 Jan
;
40
:
237
42
.
10.
Böhm
W-DU
,
Holstiege
J
,
Wenzel
S
,
Fahlenkamp
D
,
Berg
W
.
Die Nephrolithiasis im komplexen Metaphylaxesystem heute: Epidemiologische Daten zur Prävalenz und Resultate einer deutschlandweiten Praxisumfrage
.
Urologe A
.
2019
;
58
:
535
42
.
11.
Brikowski
TH
,
Lotan
Y
,
Pearle
MS
.
Climate-related increase in the prevalence of urolithiasis in the United States
.
Proc Natl Acad Sci USA
.
2008
;
105
:
9841
6
. .
12.
Siener
R
,
Laube
N
,
Strohmaier
WL
.
Rezidivprävention der Urolithiasis unter Berücksichtigung ökonomischer Aspekte
.
Urologe
.
2011
;
501276
(
10
):
1276
82
. .
13.
Nolde
A
,
Hesse
A
,
Scharrel
O
,
Vahlensieck
W
.
Modelprogramm zur Nachsorge bei rezidivierenden Harnsteinpatienten
.
Urologe
.
1993
:
33
:
148
54
.
14.
Arbeitskreis Harnsteine der Akademie der Deutschen Urologen
.
S2k-Leitlinie zur Diagnostik, Therapie und Metaphylaxe der Urolithiasis
.
DGU Harnsteine
;
2018
.
15.
Patel
SR
,
Penniston
KL
,
Nakada
SY
.
Trends in the medical management of urolithiasis: a comparison of general urologists and endourology specialists
.
Urology
.
2011
;
77
:
291
4
. .
16.
Milose
JC
,
Kaufman
SR
,
Hollenbeck
BK
,
Wolf
JS
,
Hollingsworth
JM
.
Prevalence of 24-hour urine collection in high risk stone formers
.
J Urol
.
2014
;
191
:
376
80
. .
17.
Dauw
CA
,
Alruwaily
AF
,
Bierlein
MJ
,
Asplin
JR
,
Ghani
KR
,
Wolf
JS
,
Provider variation in the quality of metabolic stone management
.
J Urol
.
2015
;
193
:
885
90
.
18.
Hess
B
.
Renal stone clinic survey: calcium stone formers’ self-declared understanding of and adherence to physician’s recommendations
.
Urolithiasis
.
2017
;
45
:
363
70
. .
19.
Dauw
CA
,
Yi
Y
,
Bierlein
MJ
,
Yan
P
,
Alruwaily
AF
,
Ghani
KR
,
Medication nonadherence and effectiveness of preventive pharmacological therapy for kidney stones
.
J Urol
.
2016
;
195
:
648
52
.
20.
Sromicki
J
,
Hess
B
.
Simple dietary advice targeting five urinary parameters reduces urinary supersaturation in idiopathic calcium oxalate stone formers
.
Urolithiasis
.
2020
;
48
:
425
33
. .
21.
Bensalah
K
,
Tuncel
A
,
Raman
JD
,
Bagrodia
A
,
Pearle
M
,
Lotan
Y
.
How physician and patient perceptions differ regarding medical management of stone disease
.
J Urol
.
2009
;
182
:
998
1004
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.